EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Severity Assessment, Guidelines, and New Therapeutic Options
|
|
- Adele Thomas
- 6 years ago
- Views:
Transcription
1 Educational Objectives EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP President-Elect, American College of Allergy, Asthma & Immunology Medical Director, Capital Allergy & Respiratory Disease Center Sacramento, CA Review methods used to assess asthma severity and control Review current guidelines for treating asthma Discuss phenotypes and endotypes in asthma and the use of biomarkers in clinical practice Examine the role of existing and potential future biologic agents in treating severe, refractory patients Definition of Asthma A chronic inflammatory disease of the airways with the following clinical features: Methods to Assess Severity and Control Episodic and/or chronic symptoms of airway obstruction Bronchial hyperresponsiveness to triggers Evidence of at least partial reversibility of the airway obstruction Alternative diagnoses are excluded Global Initiative for Asthma. Global strategy for asthma management and prevention, Available at: Clinical Evaluation of Asthma Asthma Control Current Impairment and Future Risk History and physical examination Validated questionnaires to assess severity Pulmonary function (spirometry) Biomarkers Blood eosinophil count Exhaled nitric oxide Allergy testing Global Initiative for Asthma. Global strategy for asthma management and prevention, Available at: Global Initiative for Asthma. Global strategy for asthma management and prevention, Available at: 1
2 TRACK Test for Respiratory and Asthma Control in Kids This test can help a parent determine if child s breathing problems are not under control and when medical advice should be sought. Designed for children who: Are under years of age Have a history of 2 or more episodes of wheezing, shortness of breath, or cough lasting more than 24 hours AND Have been previously prescribed bronchodilator medicines, also known as quick-relief medications, for respiratory problems OR have been diagnosed with asthma Score 80: child s breathing problems may not be under control Score 81: child s breathing problems seem to be under control Decadron and Proventil are products of MERCK & CO., Inc.; Maxair is a product of 3M Pharmaceuticals; Orapred is a product of Shionogi Pharma, Inc.; Prelone is a product of Adamis Laboratories; ProAir is a product of Teva Respiratory, LLC; Ventolin is a product of GSK; Xopenex is a product of Sunovion; The use of Primatene Mist has been discontinued in the US Score During the past 4 weeks, how often was your child bothered by breathing problems, such as wheezing, coughing, or shortness of breath? Not at all Once or twice Once every week 2 or 3 times a week 4 or more times a week During the past 4 weeks, how often did your child s breathing problems (wheezing, coughing, shortness of breath) wake him or her up at night? Not at all Once or twice Once every week 2 or 3 times a week 4 or more times a week During the past 4 weeks, to what extent did your child s breathing problems, such as wheezing, coughing, or shortness of breath, interfere with his or her ability to play, go to school, or engage in usual activities that a child should be doing at his or her age? Not at all Slightly Moderately Quite a lot Extremely During the past 3 months, how often did you need to treat your child s breathing problems (wheezing, coughing, shortness of breath) with quick-relief medications (albuterol, Ventolin, Proventil, Maxair, ProAir, Xopenex, or Primatene Mist)? Not at all Once or twice Once every week 2 or 3 times a week 4 or more times a week During the past 12 months, how often did your child need to take oral corticosteroids (prednisone, prednisolone, Orapred, Prelone, or Decadron ) for breathing problems not controlled by other medications? Never Once Twice 3 times 4 or more times Total The brands mentioned herein are trademarks of their respective owners and are not trademarks of the AstraZeneca group of companies. The makers of these brands are not affiliated with and do not endorse AstraZeneca or its products. The TRACK Test was developed by AstraZeneca. The American Academy of Pediatrics Quality Improvement Innovation Network participated in the validation of this tool. Childhood Asthma Control Test A cross-sectional study concluded that the Childhood Asthma Control Test (C- ACT) is a validated tool to assess asthma control in children, as well as identify those with inadequately controlled asthma. In the clinical setting, C-ACT can be a valuable tool based on its ease of use, alignment with asthma guidelines, validation, and input from the child and caregiver Liu AH, et al. J Allergy Clin Immunol. 2007;119: The Childhood Asthma Control Test was developed by GSK. Assessment of Asthma Control: Asthma Control Test (ACT) A longitudinal study of patients with asthma reported that ACT is reliable, valid, and responsive to changes in asthma control over time. In the clinical setting, the ACT should be a useful tool to aid physicians in identifying patients with uncontrolled asthma, facilitating their ability to follow patient progress with treatment. 1 Are Most Patients With Asthma Well-Controlled? Study Sample size Percent with uncontrolled asthma TENOR 1 1, AIM CHOICE Asthma Control Test is a trademark of QualityMetric Incorporated. 1. Schatz M, et al. J Allergy Clin Immunol. 2006;117: Chipps BE, et al. TENOR Study Group. Curr Respir Care Rep. 2012;1: Meltzer EO, et al. Allergy Asthma Proc. 2012;33: Colice GL, et al. Ann Allergy Asthma Immunol. 2012;8: Risk of Future Severe Asthma Event in Patients with Past Severe Asthma Event Severe Asthma Event Risk of severe exacerbation with history of recent exacerbation Risk of OCS treatment with history of recent OCS treatment Odds Ratio Important Factors Which Contribute to Poor Asthma Control Rhinitis and sinusitis Gastroesophageal reflux disease Low vitamin D Obesity Obstructive sleep apnea Persistent lower respiratory tract infection Psychologic (anxiety, depression) Smoking Unabated environmental trigger Poor response to therapy Chipps BE, et al. J Allergy Clin Immunol. 2012;130: Global Initiative for Asthma. Global strategy for asthma management and prevention, Available at: 2
3 Spirometry: An Important Test for Assessing Asthma Pulmonary Function Test Low FEV1 is linked to lower quality of life and higher risk of exacerbations May not be able to accurately assess level of pulmonary function from symptoms and examination May be mastered by physician and office assistant Should be assessed at least once-yearly Global Initiative for Asthma. Global strategy for asthma management and prevention, Available at: Biomarkers and Asthma Pathogenesis Biomarkers, Phenotypes, and Endotypes in Asthma Biomarkers allow physicians to determine the primary pathogenetic pathway in a given patient Th2 (Type 2) pathway Presence of interleukins 4,, and 13 Elevated blood and sputum eosinophils Present in 70% of asthma Non-Th2 pathways Inflammatory cells and cytokines poorly-characterized Epithelial Cells Play a Critical Role, as Well Oboki K, et al. Allergy Asthma Immunol Res. 2011;3:
4 Blood Eosinophils Important identifier of Th2 (Type 2) pathophysiology Most widely accepted cut-off value separating eosinophilic and non-eosinophilic = 300/mcl Eosinophil count proportional to risk of asthma exacerbation May vary significantly over time Advantage = inexpensive and widely available Blood Eosinophil Counts and Risk of Asthma Exacerbations Claims data base analysis examining eosinophil count and exacerbations requiring systemic CS or ER/hospital care Peripheral Blood Eosinophils Severe Exacerbations Acute Respiratory Events Overall Asthma Control Price DB, et al. Lancet Respir Med. 201;3: Exhaled Nitric Oxide (FeNO) Exhaled Nitric Oxide Help identify eosinophilic asthma phenotype Diagnose steroid-responsive airway inflammation Help support asthma diagnosis and etiology of respiratory symptoms Disadvantage = requires specialized equipment Dweik RA, et al. Am J Respir Crit Care Med. 2011;184: Dweik RA, et al. Am J Respir Crit Care Med. 2011;184: Important Ways to Divide Asthma Into Subtypes What is a phenotype? The outward manifestation of an individual s genetics which is the result of an interaction with the environment and which may change over time in response to new environments What is an endotype? A phenotype of a disease state which has been wellcharacterized with respect to pathophysiologic mechanisms Separation of Asthma into Clinical Phenotypes In past, asthma was characterized by the presence or absence of allergy without consideration of other characteristics Recent studies - unbiased hierarchical cluster analysis Clinical characteristics (gender, age of onset, severity) Physiology (lung function, airway hyperresponsiveness) Triggers (allergens) Sputum inflammatory cells (eosinophils, neutrophils) Sum total of characteristics are segregated into groups, with no single feature playing a predominant role in the classification 4
5 Tree Analysis Demographics and Clinical Characteristics of the SARP subjects Moore et al. Am J Respir Crit Care. 20; 181: Busse W, et al. J Allergy Clin Immunol. 2011;128: Common Endotypes of Severe Asthma Endotype Early-onset allergic Late-onset, minimally allergic Late-onset obese Late-onset nonallergic Clinical/physiologic characteristics Frequent history of atopic dermatitis, usually have allergic rhinitis Frequent chronic rhinosinusitis/polyps; more severe obstruction; may have NSAID intolerance Nonallergic, often with pulmonary restriction May have significant respiratory tract infection or GERD Inflammatory phenotype Eosinophilic Highly eosinophilic Non-eosinophilic Non-eosinophilic Current Guidelines for Treating Asthma GINA: Step-Guided Treatment What Percent of Patients are Controlled with ICS and ICS/LABA? Stratum* N Well-controlled (%) 1 - FP FP-S FP FP-S FP FP-S 68 2 Global Initiative for Asthma. Global strategy for asthma management and prevention, Available at: Use for educational purposes only. Bateman ED, et al. Am J Respir Crit Care Med. 2004;170: *Stratum 1 = no ICS Stratum 2 = < 00 mcg ICS Stratum 3 = mcg ICS
6 What is Effective for Asthma Beyond ICS/LABA? Effects of Tiotropium on FEV1 and Asthma Exacerbations Leukotriene modifiers Montelukast = leukotriene receptor antagonist Zileuton = -lipoxygenase inhibitor Neither agent shown to have benefit added to ICS/LABA in DBPC trials, although may be helpful in patients with aspirinexacerbated respiratory disease Long-acting muscarinic antagonists Effective in conjunction with ICS (in place of LABA) or as 3 rd - line therapy in addition to ICS/LABA Kerstjens HA, et al. N Engl J Med. 2012;367: Kerstjens HA, et al. N Engl J Med. 2012;367: Biologic Agents in Asthma Existing and Future Biologic Agents in Treating Severe, Refractory Asthma Unlike conventional inhaled and oral therapies for asthma, biologic agents are targeted at specific molecules responsible for asthma pathogenesis These biologic agents are typically formulated as monoclonal antibodies which are administered systemically Biologic Agents Currently Available for Severe Asthma Endotype Main target Class of agents Allergic Late-onset with eosinophilia IgE Eosinophils Anti-IgE Anti-IL Specific compounds Omalizuamb Mepolizumab Reslizumab Eosinophils Anti-IL Mepolizumab Reslizumab Benralizumab* *Submitted to FDA Anti-IgE Antibody Therapy (Omalizuamb) for Severe Allergic Asthma Humanized (9%) mab against IgE indicated in perennial allergic asthma Significant improvement of outcomes in patients receiving 3 controllers: 2% less exacerbations in patient using maximal inhaled therapy Improved asthma symptoms and AQLQ Small improvements in lung function Overall response rate 0-60% - why not higher? Absence of active inflammation Insufficient dose of drug in some patients Absence of relevant allergen exposure Mechanisms other than IgE-mediated inflammation, e.g., infection, advanced remodeling 6
7 The Targets: IL- or Eosinophils (IL-Rα) Mepolizumab: The DREAM Study Benralizumab Mepolizumab Reslizumab Eosinophil Raised levels present in 40% to 60% of asthmatics Release toxins that promote airway inflammation in asthmatic patients Blausen gallery Wikiversity Journal of Medicine. DOI:.1347/wjm/ Used for educational purposes only. IL- Principal eosinophilic regulatory cytokine Involved in the maturation, differentiation, survival, and activation of eosinophils Ortega HG, et al. N Engl J Med. 2014;371: Bel EH et al. N Engl J Med. 2014;371: Pavord ID, et al. Lancet. 2012;380: Benralizumab and Exacerbations Lung Function: % Change in FEV1 Placebo Benralizumab 20 mg By Eosinophil Status Annual Exacerbation Rate RR = 9% P =.781 RR = 36% RR = 41% P =.173 P =.096* Eosinophilic Benralizumab 2 mg RR = 22% P =.284 Noneosinophilic Benralizumab 0 mg By Baseline Eosinophil Level Annual Exacerbation Rate RR = 7% RR = 6% RR = 30% P =.822 P =.844 P =.327 RR = 24% RR = 30% RR = 43% P =.362 RR = 7% P =.131* RR = 7% P =.049* P =.024* P =.01* RR = 70% P =.002* 200 cells/μl 300 cells/μl 400 cells/μl In the overall population, significant improvement was observed for all dupilumab dose regimens vs placebo In the LEos population, significant improvement was observed for the q2w regimens vs placebo, but not for the q4w regimens Castro M, et al. Lancet Respir Med. 2014;2: Wenzel S, et al. ATS 201. Abst A6362. *P<0.0; dagger; P<0.01; P<0.001 vs placebo Dupilumab (Anti-IL-4/13Ralpha): A New Biologic Agent in Development for Severe Asthma Tezepelumab (Anti-TSLP): A New Biologic Agent in Development for Severe Asthma Adjusted annualized severe exacerbation rate, estimate (9% CI) ( ) Percentage reduction relative to placebo % -3% -71% -81% ( ) * ( ) ( ) * ( ) (n=68) (n=9) (n=66) (n=64) (n=64) Adjusted annualized severe exacerbation rate, estimate (9% CI) ( ) Placebo (n=90) Percentage reduction relative to placebo -37% -68% -43% -60% ( ) ( ) * ( ) ( ) 200 mg 300 mg 200 mg 300 mg every every every every 4 weeks 4 weeks 2 weeks 2 weeks (n=91) (n=91) (n=84) (n=92) Wenzel S, et al. Lancet. 2016;388: Corren J, et al. N Engl J Med. 2017;377:
8 Case #1 Case Studies MP is a 4-year-old white male with a 3-year history of asthma, which has been worsening over the past year Also has a 6-year history of chronic nasal congestion and postnasal drip with 2 sinus infections per year Severe wheezing and rhinorrhea after taking ASA and other NSAIDs over the last 3 years Asthma is a daily problem in spite of taking ICS/LABA and LAMA and intranasal corticosteroids for nasal/sinus symptoms He has had 4 episodes of asthma exacerbation, 3 requiring OCS, during the past year Physical Examination Nose - bilateral nasal polyps Pharynx - mucopurulent secretions in posterior pharynx Chest - bilateral wheezing and decreased air exchange Laboratory Values PFT FVC: 88% predicted FEV1: 62% predicted FEV1/FVC: % bronchodilator response FeNO = 62 ppb Absolute EOS = 44 cells/mcl Total serum IgE = 42 IU/ml Allergy skin tests = borderline reactions to ragweed and elm tree pollens Potential Therapies Leukotriene modifier, particularly zileuton (-LO inhibitor) ASA desensitization and maintenance therapy Anti-IL- antibody therapy (mepolizumab or reslizumab) Effectiveness of Various Medications in AERD A survey analyzing patient observations of treatment effectiveness in those with AERD showed that aspirin was most beneficial, followed by a leukotriene receptor agonist and a combination of medicines. However, the majority of patients reported that no medication made a difference in symptoms. Despite ongoing medical therapy, the burden of disease remains high in these patients. Ta V, White A. J Allergy Clin Immunol Pract. 201;3:
9 Long-term Aspirin Therapy Goal = ASA 60 mg BID Reduces nasal congestion, anosmia, recurrent sinusitis Similar asthma control with less OCS Difficult to maintain long term due to gastritis Case #2 LS is a 36-year-old woman with asthma since age 8 years; has been worsening over past 2 years Also has had year-around nasal congestion, sneezing, and itchy eyes and nose since childhood with seasonal worsening in the spring and fall seasons for the same length of time Had flexural eczema in childhood, and now has frequent skin dryness and erythema over her neck and occasionally around her eyes Has been treated with medium-dose ICS/LABA and oral H1 antihistamine for past year but has continued to have some daily symptoms and had 3 asthma exacerbations in the past year requiring OCS Her home environment is noteworthy for a pet rabbit Physical Examination Nose pale, swollen inferior nasal turbinates and watery, clear secretions bilaterally Chest examination clear Skin mild erythema and papulation on her anterior neck Laboratory Values PFT FVC: 92% predicted FEV1: 74% predicted FEV1/FVC: % bronchodilator response FeNO = 3 ppb Absolute EOS = 3 cell/mcl Total serum IgE = 276 IU/ml Allergy skin tests = large reactions to Dermatophagoides pteronyssinus (dust mite) and Alternaria mold; negative to rabbit dander Potential Therapies Leukotriene modifier, particularly montelukast LAMA Anti-IgE antibody therapy (omalizumab) Key Points to Improve Adherence Use effective techniques to promote open communication Ask patient s or parent s concerns and goals for the visit Ask for any concerns patients or parents have about medicines (e.g. safety, impact, convenience, and cost) Assess patient s and family s perceptions of the severity level of the disease and how well it is controlled Assess level of family and social support Assess levels of stress, anxiety and depression Assess ability to adhere to a written asthma action plan 9
10 Patient Education: Expert Panel Recommendation - NAEPP Clinicians teach patients and families the basic facts about asthma (especially the role of inflammation), need for each medicine, especially inhaled steroids, medication skills, and self-monitoring techniques (Evidence A) Provide all patients with a written asthma action plan: Daily management Recognize and handle worsening asthma Written action plans are particularly recommended for patients who have moderate or severe persistent asthma, a history of severe exacerbations, or poorly controlled asthma (Evidence B) Clinicians teach patients environmental control measures Summary A significant proportion of patients with asthma have poorly controlled symptoms Asthma may be divided into a number of phenotypes and endotypes which is partly predicated upon inflammatory cell infiltration into the airways Patients with highly eosinophilic asthma are more likely to have more severe disease with recurrent exacerbations Current and future biologic therapies have targeted specific molecules (such as IgE and IL-) and inhibition of these targets may reduce symptoms and exacerbations significantly Inhibition of IL-4 IL-13 axis helps both atopic dermatitis and asthma NAEPP. Accessed via Thank you!
Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationAsthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient Mario Castro MD, MPH Asthma & Airway Translational Research Unit Washington University School of Medicine St.
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationSevere Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationSevere Asthma & Exacerbations: Dawn of a New Era?
Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation,
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationDisclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationTreatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology
Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationLINEE GUIDA DELL ASMA: UP TO DATE
LINEE GUIDA DELL ASMA: UP TO DATE Azienda Ospedaliera Pisana Università degli Studi di Pisa Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic and Vascular Department,
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationRising Incidence of Asthma
Controlling Severe Asthma through Advanced Diagnosis and Treatment Strategies James F. Donohue, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine University of North Carolina at
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationJamie Lee Memorial Lecture ( ) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab
Jamie Lee Memorial Lecture (1958-2017) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab Larry Borish, M.D. Professor of Medicine and Microbiology University of Virginia Conflict of Interest
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationDistinguishing Type-2 Asthma
UPDATE ON ASTHMA THERAPY: MATCHING PHENOTYPE TO TREATMENT Sally E. Wenzel, MD Professor of Medicine University of Pittsburgh Asthma Institute@UPMC Subsection Chief of Allergy 1234567 891234 567891 2345678
More informationAddressing Unmet Medical Needs in Severe Asthma: Where Do We Stand?
Addressing Unmet Medical Needs in Severe Asthma: Where Do We Stand? An Expert Consensus Presented by: Michael Blaiss, MD, FACAAI Mario Castro, MD, MPH Provided by the American College of Allergy, Asthma
More informationPediatric Asthma: Pharmacotherapy. Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado
Pediatric Asthma: Pharmacotherapy Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado Pediatric Asthma: Pharmacotherapy Disclosures/Conflicts of Interest:
More informationasthma, order-made medicine, phenotypes 2.1 Cluster analysis by Haldar et al.
Received: 8 June 2015 Accepted: 25 February 2016 DOI: 10.1002/jgf2.7 REVIEW ARTICLE Asthma phenotypes Masahiro Hirose MD, PhD Takahiko Horiguchi MD, PhD Department of Respiratory Medicine II, Fujita Health
More informationAsthma in Pregnancy. Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA. Introduction
Asthma in Pregnancy Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA Introduction Asthma is the most common potentially serious medical problem to complicate
More informationFunction of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)
Function of the Respiratory System Exchange CO2 (on expiration) for O2 (on inspiration) Upper Respiratory Tract Includes: Nose Mouth Pharynx Larynx Function: Warms and humidifies the inspired air Filters
More informationAsthma and Vocal Cord Dysfunction
Asthma and Vocal Cord Dysfunction Amy L. Marks DO, FACOP Pediatric Allergy and Immunology Assistant Professor of Pediatrics Oakland University William Beaumont School of Medicine Objectives: Understanding
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationNancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
More informationUpdate on Biologicals for ABPA and Asthma
Update on Biologicals for ABPA and Asthma 5 th Advances Against Aspergillosis Istanbul 27 Jan 2012 Richard B. Moss MD Professor of Pediatrics Stanford University Palo Alto CA USA Disease of chronic airway
More informationThe Pharmacist s Role in Managing Severe Asthma. This activity is supported by an educational grant from Genentech. Educational Objectives
The Pharmacist s Role in Managing Severe Asthma Jennifer M. Malinowski, PharmD, RPh Assistant Dean, Academic Affairs Associate Professor, Pharmacy Practice Wilkes University School of Pharmacy Wilkes-Barre,
More informationExhaled Nitric Oxide Today s Asthma Biomarker. Richard F. Lavi, MD FAAAAI FAAP
Exhaled Nitric Oxide Today s Asthma Biomarker Richard F. Lavi, MD FAAAAI FAAP Objectives Describe exhaled nitric oxide physiology and pathophysiology Review the current literature regarding exhaled nitric
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationTreatment of Severe Asthma: Biologics to Bronchial Thermoplasty. Disclosures
Treatment of Severe Asthma: Biologics to Bronchial Thermoplasty Monica Kraft, M.D. Robert and Irene Flinn Professor of Medicine Chair, Department of Medicine Deputy Director, Asthma and Airway Disease
More informationAsthma Update I have no professional or personal financial conflicts of interest to disclose.
Asthma Update 2018 Disclosures Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center I have
More informationAsthma Update Jennifer W. McCallister, MD, FACP, FCCP
Asthma Update 2018 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical Center Disclosures I have
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationDifferent kinds of asthma, different kinds of therapies
Different kinds of asthma, different kinds of therapies Friday 10 th November 2017 XXXIII Congresso Sezione SIAAIC Toscana Professor Neil Barnes Medical Head Global Respiratory Franchise, GSK Brentford,
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationPublic Dissemination
1. THE ASTHMA CONDITION 9 18 3 30 A. Pathophysiology 4 6 0 10 1. Teach an individual with asthma and their family using simple language by illustrating the following with appropriate educational aids a.
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationOmalizumab (Xolair) NHLBI normal ranges by age for FEV 1/FVC 8-19 years of age 85%; years of age 80%;
DRAFT Medical Coverage Policy Injectable Agents for Asthma and Chronic Idiopathic Urticaria Fasenra, Nucala, Xolair, Cinqair EFFECTIVE DATE: 03 01 2018 POLICY LAST UPDATED: 03 20 2018 OVERVIEW This policy
More information5/1/18. Emerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationTARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS
TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Recommendation PULMONARY FUNCTION TESTING (SPIROMETRY) Conditional: The Expert Panel that spirometry measurements FEV1,
More informationEmerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationOptimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers?
Disclosures: Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Stanley Fineman, MD Past-President, American College of Allergy, Asthma & Immunology Adjunct Associate
More informationUPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER
JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER UPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA OBJECTIVES Describe Describe asthma medications that have been added
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationImproving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
More informationAsthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationSignificance. Asthma Definition. Focus on Asthma
Focus on Asthma (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Asthma Definition Chronic inflammatory disorder of airways Causes airway hyperresponsiveness
More informationDoes rhinitis. lead to asthma? Does sneezing lead to wheezing? What allergic patients should know about the link between allergic rhinitis and asthma
Does rhinitis lead to asthma? Does sneezing lead to wheezing? What allergic patients should know about the link between allergic rhinitis and asthma For a better management of allergies in Europe Allergy
More informationBiologicals in the management of bronchial asthma. Deepa Shrestha
Biologicals in the management of bronchial asthma Deepa Shrestha Overview of the seminar Burden of asthma and need of biologicals Immunology of asthma Possible targeted therapy Available biologicals used
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationSEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI IL-5 ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA
SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA FIND OUT MORE VISIT - WWW.NUCALA.CO.UK Vial not actual size
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationAllergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
More informationAn Insight into Allergy and Allergen Immunotherapy Co-morbidities of allergic disease
An Insight into Allergy and Allergen Immunotherapy Co-morbidities of allergic disease Carmen Vidal Athens, September 11, 2014 Pucci S & Incorvaia C, 2008; 153:1-2 1. The major player in driving the immune
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationPolicy Effective 4/1/2018
Corporate Medical Policy Interleukin-5 Antagonists Notification File Name: Origination: Last CAP Review: Next CAP Review: Last Review: interleukin_5_antagonists 2/2016 11/2017 11/2018 2/2018 Policy Effective
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationAilléirge Péidiatraiceach. Pediatric Allergy 3/9/2018. Disclosures & Conflicts Of Interest
Ailléirge Péidiatraiceach Michael Zacharisen, M.D. Allergy/Immunology Pediatric Allergy Michael Zacharisen, M.D. Allergy/Immunology Disclosures & Conflicts Of Interest Green Bay Packer fan I drive a Jeep
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationEmerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationImmunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationAsthma By Mayo Clinic staff
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationAn Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
An Update on Allergic Rhinitis Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Allergic Rhinitis Common condition with increasing prevalence
More informationBrooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C
Brooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C Associate Professor of Pharmacy Practice Southwestern Oklahoma State University College of Pharmacy Oklahoma Society of Health System Pharmacists Annual Meeting
More information